---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-191839"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2023-07-24T23:59:59+00:00"
generated_at: "2026-06-13T04:16:14.492956+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics to acquire EryDel for up to 7.25M shares + $485M milestones

## Summary
- EryDel shareholders get up to 7,250,352 shares (16.7% of combined company) and up to $485M in milestone cash payments, no royalties.
- Quince assumes EryDel's $13M (€10M) EIB loan; payments start H2 2026.
- Preliminary cash, equivalents, and short-term investments of ~$87.6M as of June 30, 2023 to fund operations into 2026.
- CMO Karen Smith to depart effective September 1, 2023; Luca Benatti to join board upon closing.
- Acquisition includes Phase 3 asset EryDex for Ataxia-Telangiectasia under FDA SPA; close expected Q3 2023.

## SEC filing metadata
- accession: 0001193125-23-191839
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2023-07-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 3.02, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312523191839/0001193125-23-191839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312523191839/d542769d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-191839
- JSON: https://secwatch.observer/filing/0001193125-23-191839.json
- Plain text: https://secwatch.observer/filing/0001193125-23-191839.txt

## Key facts
- Debt Financings
  Quince Therapeutics, Inc. incurred loan of $13 million (€10 million in principal) with European Investment Bank (EIB).
  - Instrument: loan
  - Principal: $13 million (€10 million in principal)
  - Counterparty: European Investment Bank (EIB)
  - Event: incurrence
  source text: In connection with and contingent upon the consummation of the EryDel Acquisition, the Company will assume EryDel’s $13 million (€10 million in principal) European Investment Bank (EIB) loan with scheduled payments beginning in the second half of 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523191839/0001193125-23-191839-index.htm
- Executive change
  Karen Smith departed as Chief Medical Officer at Quince Therapeutics, Inc..
  - Action: leaving
  - Role: Chief Medical Officer
  source text: On July 24, 2023, the Company announced that Karen Smith, Chief Medical Officer of the Company, would be leaving the Company, effective September 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523191839/0001193125-23-191839-index.htm
- Executive change
  Luca Benatti was appointed as director at Quince Therapeutics, Inc..
  - Action: appointed
  - Role: director
  source text: On July 21, 2023, the Company Board of Directors approved the appointment of Luca Benatti to serve as a director of the Company, contingent and effective upon the closing of the EryDel Acquisition.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523191839/0001193125-23-191839-index.htm
- Material Agreements
  Quince Therapeutics, Inc. entered into Stock Purchase Agreement with EryDel S.p.A. and the EryDel Shareholders valued at up to $485,000,000 in potential cash payments (effective 2023-07-21).
  - Action: entry
  - Agreement: merger
  - Counterparty: EryDel S.p.A. and the EryDel Shareholders
  - Value: up to $485,000,000 in potential cash payments
  - Effective: 2023-07-21
  source text: On July 21, 2023 (the “Agreement Date”), Quince Therapeutics, Inc., a Delaware corporation (the “Company”), EryDel Italy, Inc., a Delaware corporation and wholly owned indirect subsidiary of the Company, EryDel S.p.A, a company with shares incorporated under the laws of Italy, (“EryDel”), holders of EryDel capital stock and the managers of EryDel (the “EryDel Shareholders”) and Shareholder Representative Services LLC, a Colorado limited liability company solely in its capacity as the representative, agent and attorney-in-fact of the EryDel Shareholders, entered into a Stock Purchase Agreement (the “Purchase Agreement”), pursuant to which, and subject to the terms and conditions set forth in the Purchase Agreement, the Company will indirectly acquire all of the outstanding equity interests of EryDel (the “EryDel Acquisition”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312523191839/0001193125-23-191839-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.